Research Summary

My research is focused on understanding regulation of cell signaling by post-tranlational modifications in cancer cells. Specifically, we are using targeted proteomic techniques to study phosphorylation dynamics in key signaling networks such as EGFR, RAS/ERK, and AKT/mTOR. The studies are aimed at identifying key regulatory phosphorylation sites relevant to tumor development, progression, response to targeted therapies, and development of resistance. As part of this effort, we are working on novel approaches for quantifying site-specific phosphorylation of low-abundance proteins, such as transcription factors and other nuclear targets of the intracellular signal transduction pathways.

Education

University of California, Berkeley, B.A., 05/1999, Molecular and Cell Biology
University of California, San Francisco, PhD, 06/2006, Biomedical Sciences
University of California, San Francisco, MD, 05/2008, Medicine, Medical Scientist Training Program
University of California, San Francisco, Residency, 7/08-6/10, Anatomic Pathology
University of California, San Francisco, Fellowship, 7/10-6/11, Pulmonary and Surgical Pathology
University of California, San Francisco, Chief Resident, 7/10-6/11, Anatomic Pathology
University of California, San Francisco, Post-doc, 7/11-6/16, Biology of lung cancer
University of California, San Francisco, Post-doc, 7/11-6/16, Proteomics of signaling

Selected Publications

  1. Whitney Tamaki, Daniel L. Kerr, Wei Wu, Grant Eilers, Anatoly Urisman, Yu-Ting Chou, Philippe Gui, Shigeki Nanjo, Johannes R. Kratz, David M. Jablons, Trever G. Bivona, Collin M. Blakely. Abstract C025: Identification of cell-cell signaling programs across the tumor-tumor microenvironment ecosystem and associated with clinical status in neoadjuvant osimertinib treated patient samples revealed by spatial profiling. Cancer Research. 2024 Nov 17; 84(22_Supplement):c025-c025.  View on PubMed
  2. Khorsandi N, Han HS, Rajalingam R, Shoji J, Urisman A. De novo and recurrent post-transplant membranous nephropathy cases show similar rates of concurrent antibody-mediated rejection. Front Nephrol. 2024; 4:1438065.  View on PubMed
  3. Blakely CM, Urisman A, Gubens MA, Mulvey CK, Allen GM, Shiboski SC, Rotow JK, Chakrabarti T, Kerr DL, Aredo JV, Bacaltos B, Gee M, Tan L, Jones KD, Devine WP, Doebele RC, Aisner DL, Patil T, Schenk EL, Bivona TG, Riess JW, Coleman M, Kratz JR, Jablons DM. Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study. J Clin Oncol. 2024 Sep 10; 42(26):3105-3114.  View on PubMed
  4. Riley AK, Grant M, Snell A, Cromwell E, Vichas A, Moorthi S, Rominger C, Modukuri SP, Urisman A, Castel P, Wan L, Berger AH. The deubiquitinase USP9X regulates RIT1 protein abundance and oncogenic phenotypes. iScience. 2024 Aug 16; 27(8):110499.  View on PubMed
  5. Alessandro Mauro Mozzarelli, Antonio Cuevas-Navarro, Anatoly Urisman, Pau Castel. Abstract 3938: A novel mouse model reveals potential therapeutic strategies for RIT1-driven lung adenocarcinomas. Cancer Research. 2024 Mar 22; 84(6_Supplement):3938-3938.  View on PubMed
  6. Li Y, Pillar N, Li J, Liu T, Wu D, Sun S, Ma G, de Haan K, Huang L, Zhang Y, Hamidi S, Urisman A, Keidar Haran T, Wallace WD, Zuckerman JE, Ozcan A. Virtual histological staining of unlabeled autopsy tissue. Nat Commun. 2024 Feb 23; 15(1):1684.  View on PubMed
  7. Riley AK, Grant M, Snell A, Vichas A, Moorthi S, Urisman A, Castel P, Wan L, Berger AH. The deubiquitinase USP9X regulates RIT1 protein abundance and oncogenic phenotypes. bioRxiv. 2023 Dec 01.  View on PubMed
  8. Murphy JD, Caza TN, Cassol CA, Storey A, Ambruzs JM, Boils C, Walker PD, Sharma S, Messias N, Hennigar R, Andeen NK, VanBeek C, Palmer M, Sankar L, Sanghi P, Dinesh K, Dicker L, Urisman A, Larsen CP. Clinicopathologic Features of Antibrush Border Antibody Disease. Kidney Int Rep. 2024 Feb; 9(2):370-382.  View on PubMed
  9. Joel D. Murphy, Tiffany Caza, Clarissa A. Cassol, Patrick D. Walker, Shree G. Sharma, Josephine M. Ambruzs, Christie L. Boils, Nicole K. Andeen, Matthew Palmer, Anatoly Urisman, Christopher P. Larsen. Clinicopathologic Features of Anti-Brush Border Antibody Disease: A Series of 66 Patients. Journal of the American Society of Nephrology. 2023 Nov 1; 34(11S):43-43.  View on PubMed
  10. Jacqueline V. Aredo, Anatoly Urisman, Matthew A. Gubens, Claire Mulvey, Greg M. Allen, Julia K. Rotow, Daniel Lucas Kerr, Turja Chakrabarti, Bianca Bacaltos, Megan Gee, Kirk Jones, Dara L. Aisner, Tejas Patil, Erin Lynn Schenk, Trever G. Bivona, Jonathan W. Riess, Melissa Coleman, Johannes Ruediger Kratz, David Jablons, Collin M. Blakely. Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR -mutated non-small cell lung cancer. Journal of Clinical Oncology. 2023 Jun 1; 41(16_suppl):8508-8508.  View on PubMed
  11. Ye J, Croom N, Troxell ML, Kambham N, Zuckerman JE, Andeen N, Dall'Era M, Hsu R, Walavalkar V, Laszik ZG, Urisman A. Non-Full House Membranous Lupus Nephritis Represents a Clinically Distinct Subset. Kidney360. 2023 07 01; 4(7):935-942.  View on PubMed
  12. Lopez J, Bonsor DA, Sale MJ, Urisman A, Mehalko JL, Cabanski-Dunning M, Castel P, Simanshu DK, McCormick F. The ribosomal S6 kinase 2 (RSK2)-SPRED2 complex regulates the phosphorylation of RSK substrates and MAPK signaling. J Biol Chem. 2023 06; 299(6):104789.  View on PubMed
  13. Sadiq S, Urisman A, Cil O. Case report: Short-term eculizumab use in atypical HUS associated with Lemierre's syndrome and post-infectious glomerulonephritis. Front Med (Lausanne). 2023; 10:1167806.  View on PubMed
  14. B. Bromberger, F. McLafferty, J. Smith, B. Elicker, K. Jones, C. Mulvey, A. Urisman, A. Venado, S. Hays, J. Kukreja, B. Trinh. Bilateral Lung Transplant with Recognition of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) of rhe Donor Lungs in the Immediate Postoperative Period. The Journal of Heart and Lung Transplantation. 2023 Apr 1; 42(4):s373-s374.  View on PubMed
  15. Waldman M, Sinaii N, Lerma EV, Kurien AA, Jhaveri KD, Uppal NN, Wanchoo R, Avasare R, Zuckerman JE, Liew A, Gallan AJ, El-Meanawy A, Yagil Y, Lebedev L, Baskaran K, Vilayur E, Cohen A, Weerasinghe N, Petrakis I, Stylianou K, Gakiopoulou H, Hamilton AJ, Edney N, Millner R, Marinaki S, Rein JL, Killen JP, Rodríguez Chagolla JM, Bassil C, Lopez Del Valle R, Evans J, Urisman A, Zawaideh M, Baxi PV, Rodby R, Vankalakunti M, Mejia Vilet JM, Ramirez Andrade SE, Homan MP, Vásquez Jiménez E, Perinpanayagam N, Velez JCQ, Mohamed MMB, Mohammed KMG, Sekar A, Ollila L, Aron AW, Arellano Arteaga KJ, Islam M, Berrio EM, Maoujoud O, Morales RR, Seipp R, Schulze CE, Yenchek RH, Vancea I, Muneeb M, Howard L, Caza TN. COVID-19 Vaccination and New Onset Glomerular Disease: Results from the IRocGN2 International Registry. Kidney360. 2023 03 01; 4(3):349-362.  View on PubMed
  16. Essien F, Evans J, Kyle A, Urisman A, Adams N. 'Granulomatosis with polyangiitis after Pfizer vaccination': a case report. Ther Adv Rare Dis. 2022 Jan-Dec; 3:26330040221130084.  View on PubMed
  17. Basso P, Dang EV, Urisman A, Cowen LE, Madhani HD, Noble SM. Deep tissue infection by an invasive human fungal pathogen requires lipid-based suppression of the IL-17 response. Cell Host Microbe. 2022 11 09; 30(11):1589-1601.e5.  View on PubMed
  18. Rachel R. Johnson, Anatoly Urisman, Kerry C. Cho, Ramin Sam, Sandy W. Wong. Outcomes for Patients With Renal AA Amyloidosis Associated With Injection Heroin Use. Journal of the American Society of Nephrology. 2022 Nov 1; 33(11S):864-864.  View on PubMed
  19. Bons J, Pan D, Shah S, Bai R, Chen-Tanyolac C, Wang X, Elliott DRF, Urisman A, O'Broin A, Basisty N, Rose J, Sangwan V, Camilleri-Broët S, Tankel J, Gascard P, Ferri L, Tlsty TD, Schilling B. Data-independent acquisition and quantification of extracellular matrix from human lung in chronic inflammation-associated carcinomas. Proteomics. 2023 04; 23(7-8):e2200021.  View on PubMed
  20. Bean GR, Najjar S, Shin SJ, Hosfield EM, Caswell-Jin JL, Urisman A, Jones KD, Chen YY, Krings G. Correction to: Genetic and immunohistochemical profiling of small cell and large cell neuroendocrine carcinomas of the breast. Mod Pathol. 2022 Oct; 35(10):1494-1495.  View on PubMed

Go to UCSF Profiles, powered by CTSI